Tim Boreham

3 weeks ago | stockhead.com.au | Tim Boreham

Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injuryPreclinical work has shown a significant reduction in secondary brain injury and cardiac damageCEO James Bonnar spent 15 years at Neuren Pharmaceuticals in the company’s formative stageNyrada (ASX:NYR) CEO James Bonnar is too modest to admit it, but he played a key role in developing and commercialising Neuren Pharmaceuticals’ (ASX:NEU) neurological drug Daybue.

3 weeks ago | stockhead.com.au | Tim Boreham

Medadvisor and Dimerix lead the valuation gains in a choppy monthEmvision and Paradigm open more pivotal trial sitesCapital raisings click overMedAdvisor (ASX:MDR) is the ASX hero biotech of an otherwise subdued May, stacking on more than 52% in market capitalisation for the month. The medication compliance group said it had found a probable buyer for its Australian operations, thus spurring the rally.

3 weeks ago | stockhead.com.au | Tim Boreham

For Vitrafy Life Sciences (ASX:VFY) chief Kate Munnings, two isolated local controversies are testament to how the recently listed cryopreservation outfit’s technology can be put to good use. “With every problem there’s an opportunity,” she says. The first incident was Monash IVF’s mishandling of biological samples that led to a mother being implanted with the wrong embryo.

3 weeks ago | stockhead.com.au | Tim Boreham

Opthea and Patrys report they are still alive after failing to reach the summit, but the line’s a bit cracklyRenerve in Berkeley tie up for soft tissue repairImugene furthers trial of ‘off Broadway’ assetWith the Everest climbing season at its peak, the news from the ‘death zone’ is that the stricken Opthea is still alive. Can the company execute an organised descent?

4 weeks ago | stockhead.com.au | Tim Boreham

The unlisted Healthscope’s misfortune casts the spotlight on the listed Ramsay Health CarePrivate hospital profitability has shrunk, but the sector still accounts for more than 40% of admissionsRamsay’s rehab includes putting its loss-making French business up for salePrivate hospital operator Healthscope’s lapse into administration this week highlights the role sector’s financial woes that have been brewing for years – along with that of the private equity owner’s excessive debt.